

APPENDIX VI

STATUTORY AND GENERAL INFORMATION

A. FURTHER INFORMATION ABOUT OUR COMPANY

1. Incorporation of Our Company

Our Company was incorporated in the PRC as a limited liability company on September 26, 2016 and was converted to a joint stock company with limited liability on April 25, 2022 under the PRC Company Law.

We have established a principal place of business in Hong Kong at Room 1910, 19/F, Lee Garden One, 33 Hysan Avenue, Causeway Bay, Hong Kong and have been registered with the Registrar of Companies in Hong Kong as a non-Hong Kong company under Part 16 of the Companies Ordinance on January 22, 2026. Ms. Sham Ying Man, one of our joint company secretaries, has been appointed as the authorized representative of our Company for the acceptance of service of process and notices in Hong Kong, whose correspondence address is at Room 1910, 19/F, Lee Garden One, 33 Hysan Avenue, Causeway Bay, Hong Kong.

As the Company was incorporated in the PRC, our corporate structure and Articles of Association are subject to the relevant PRC Law. A summary of the relevant PRC Laws and regulations and of the Articles of Association is set out in “Regulatory Overview,” Appendix IV and V, respectively.

2. Changes in the Share Capital of Our Company

Assuming the [REDACTED] is not exercised, upon completion of the [REDACTED], our issued share capital will increase to RMB[REDACTED], made up of [REDACTED] Domestic Shares and [REDACTED] H Shares (including [REDACTED] Converted H Shares) fully paid up or credited as fully paid up, representing [REDACTED]% and [REDACTED]% of our registered share capital, respectively. For further details, please refer to the section headed “Share Capital” in this document.

Save as disclosed above and in the section headed “History, Development and Corporate Structure” in this document, there has been no alteration in the share capital of our Company within two years immediately preceding the date of this document.

3. The Shareholders’ Resolutions of Our Company

At our Shareholders’ meeting held on January 15, 2026, the following resolutions, among other things, were duly passed:

- (i) the sub-division of the Shares with nominal value of RMB1.00 each on the basis of one to two (the “**Share Subdivision**”), and taking into account the Share Subdivision, the [REDACTED] of H Shares of nominal value of RMB0.5 each and such H Shares be [REDACTED] on the Hong Kong Stock Exchange;
- (ii) the number of H shares to be [REDACTED] shall be up to [REDACTED], and the grant of the [REDACTED] in respect of no more than [REDACTED]% of the number of H Shares [REDACTED] pursuant to the [REDACTED];
- (iii) authorization of the Board or its authorized individual to handle all matters relating to, among other things, the [REDACTED], the [REDACTED] and [REDACTED] of [REDACTED] on the Hong Kong Stock Exchange; and
- (iv) subject to the completion of the [REDACTED], the conditional adoption of the revised Articles of Association, which shall become effective on the [REDACTED], and the Board has been authorized to amend the Articles of Association in accordance with any comments from the Stock Exchange and the relevant PRC regulatory authorities and for the purpose of its filing with the relevant regulatory authorities.

APPENDIX VI

STATUTORY AND GENERAL INFORMATION

4. Changes in the Share Capital of Our Subsidiary

Our only subsidiary, Therapeutics Technology, was incorporated in the PRC on May 9, 2026 with registered capital of RMB10 million.

Save as disclosed above, there have been no alterations in the share capital of our subsidiary within the two years immediately preceding the date of this document.

5. Corporate reorganization

Our Company has not gone through any corporate reorganization for the purpose of the [REDACTED]. For more details on the history and development of our Company, please refer to the section headed “History, Development and Corporate Structure” in this document.

6. Restrictions on Share Repurchases

For more details, please refer to “Appendix IV — Summary of Principal Laws and Regulations” and “Appendix V — Summary of the Articles of Association” in this document.

B. FURTHER INFORMATION ABOUT OUR BUSINESS

1. Summary of Material Contracts

The following contracts (not being contracts entered into in the ordinary course of business) were entered into by our Company within the two years preceding the date of this document and are or may be material:

- (a) a capital injection agreement dated September 14, 2024 entered into by, among other parties, PrimeGenX Therapeutics Co., Ltd. (北京普祺醫藥科技股份有限公司), Beijing Yitang Chuangxin Venture Capital Center (Limited Partnership) (北京屹唐創欣創業投資中心(有限合夥)), Beijing Yitang Dingxin Technology Partnership (北京屹唐鼎芯科技合夥企業(有限合夥)) and other parties agreed to subscribe for additional registered capital of the Company;
- (b) the termination of special rights agreement dated January 15, 2026 entered into by, among other parties, Chongqing Xianfeng Qiyun Equity Investment L.P. (重慶險峰旗雲股權投資合夥企業(有限合夥)), Hangzhou Yuhang Lapam Healthcare Equity Investment Fund Partnership (Limited Partnership) (杭州余杭龍磐健康醫療股權投資基金合夥企業(有限合夥)), Beijing Kaiyuan Hongdao Venture Capital Center (Limited Partnership) (北京開元弘道創業投資中心(有限合夥)), Xizang Zhifan Enterprise Management Consulting Center (Limited Partnership) (西藏智梵企業管理諮詢中心(有限合夥)), Nanjing Lestar Medical Technology Partnership (Limited Partnership) (南京力思達醫療科技合夥企業(有限合夥)), Heze Jurong Biomedical Investment Fund Management Partnership (Limited Partnership) (荷澤聚融生物醫藥投資基金管理合夥企業(有限合夥)), Jiaxing Zhenyan Micifang Equity Investment Partnership (Limited Partnership) (嘉興箴言幕次方股權投資合夥企業(有限合夥)), Beijing Medical and Health Industry Investment Fund (Limited Partnership) (北京市醫藥健康產業投資基金(有限合夥)), Beijing Yitang Chuangxin Venture Capital Center (Limited Partnership) (北京屹唐創欣創業投資中心(有限合夥)), Beijing Shoufazhan Huaxia Longying Jielian Technology Investment Fund (Limited Partnership) (北京首發展華夏龍盈接力科技投資基金(有限合夥)), Beijing Beike Zhengqi Guoxin Pharmaceutical Industry Investment Fund (Limited Partnership) (北京北科正奇國信醫藥產業投資基金(有限合夥)), PrimeGenX Therapeutics Co., Ltd. (北京普祺醫藥科技股份有限公司) and Mr. Li Yuliang (李雨亮), pursuant to which certain shareholders’ special rights were terminated and will cease to have any effect (i) one day before the first filing of the first application for the [REDACTED] (subject to certain reinstatement mechanism), or (ii) upon [REDACTED], as the case may be; and
- (c) [REDACTED].

APPENDIX VI STATUTORY AND GENERAL INFORMATION

2. Our Material Intellectual Property Rights

As of the Latest Practicable Date, we have registered or have applied for the registration of the following intellectual property rights which are material in relation to our business.

(a) Trademarks

As of the Latest Practicable Date, we have registered the following trademarks which are material to our business:

No.	Trademark	Class	Registered Owner	Place of Registration	Registration Number	Expiry Date
1. . . .	puqipharma	5	Our Company	PRC	70416511	September 20, 2033
2. . . .	puqipharma	42	Our Company	PRC	70405863	December 6, 2033
3. . . .	puqipharma	3	Our Company	PRC	70402136	December 6, 2033
4. . . .	puqipharma	44	Our Company	PRC	70396177	September 20, 2033
5. . . .	puqipharma	1	Our Company	PRC	70394487	September 20, 2033
6. . . .	puqipharma	10	Our Company	PRC	70391386	September 20, 2033
7. . . .		5	Our Company	PRC	59287536	March 13, 2032
8. . . .		42	Our Company	PRC	59286419	March 13, 2032
9. . . .		1	Our Company	PRC	59284303	May 13, 2032
10. . . .		35	Our Company	PRC	59283503	May 13, 2032
11. . . .		10	Our Company	PRC	59281943	March 6, 2032
12. . . .		3	Our Company	PRC	59281875	June 6, 2032
13. . . .		3	Our Company	PRC	59277238	May 13, 2032
14. . . .		5	Our Company	PRC	59274740	May 13, 2032

APPENDIX VI STATUTORY AND GENERAL INFORMATION

No.	Trademark	Class	Registered Owner	Place of Registration	Registration Number	Expiry Date
15. . . .		44	Our Company	PRC	59271686	March 13, 2032
16. . . .		35	Our Company	PRC	59266503	May 13, 2032
17. . . .		1	Our Company	PRC	59266081	March 6, 2032
18. . . .		42	Our Company	PRC	59265266	May 13, 2032
19. . . .		10	Our Company	PRC	59262621	March 13, 2032
20. . . .		44	Our Company	PRC	59285053	May 13, 2032

(b) Patents

Please refer to the paragraph headed “Business — Intellectual Property” for patents registered and patents applications as of the Latest Practicable Date which we consider to be or may be material to our business.

(c) Copyrights

As of the Latest Practicable Date, we have registered the following copyrights which are material to our business:

No.	Copyright	Owner	Registration Number	Registration Date	Place of Registration
1. . . .	L-Prolinamide Solubility Analysis and Management System V1.0 (L-脯氨酸溶解度分析及管理系统V1.0)	Our Company	2019SR0928642	September 6, 2019	PRC
2. . . .	Abiraterone Acetate Residual Solvent Detection and Analysis System V1.0 (醋酸阿比特龙残留溶剂检测分析系统V1.0)	Our Company	2019SR0928699	September 6, 2019	PRC
3. . . .	Dehydroepiandrosterone Acetate Specific Optical Rotation Determination System V1.0 (醋酸去氢表雄酮比旋光度测定系统V1.0)	Our Company	2019SR0930282	September 6, 2019	PRC

APPENDIX VI STATUTORY AND GENERAL INFORMATION

No.	Copyright	Owner	Registration Number	Registration Date	Place of Registration
4. . . .	PrimeGenX Quality Control Platform V1.0 (普祺醫藥質量控制平台V1.0)	Our Company	2019SR0927204	September 5, 2019	PRC
5. . . .	Vildagliptin Residual Solvent Detection and Analysis System V1.0 (維格列汀殘留溶劑檢測分析系統V1.0)	Our Company	2019SR0927198	September 5, 2019	PRC
6. . . .	Vildagliptin Tablet Hardness and Content Detection System V1.0 (維格列汀片硬度及含量檢測系統V1.0)	Our Company	2019SR0928731	September 6, 2019	PRC
7. . . .	Abiraterone Acetate Tablet Formulation Moisture Control Platform V1.0 (一種醋酸阿比特龍片制劑水分控制平台V1.0)	Our Company	2019SR0928601	September 6, 2019	PRC
8. . . .	PrimeGenX Therapeutics Co., Ltd. LOGO1 (北京普祺醫藥科技股份有限公司LOGO1)	Our Company	Guo Zuo Deng Zi (國作登字)-2022-F-10010419	January 17, 2022	PRC
9. . . .	PrimeGenX Therapeutics Co., Ltd. LOGO3 (北京普祺醫藥科技股份有限公司LOGO3)	Our Company	Guo Zuo Deng Zi (國作登字)-2022-F-10010420	January 17, 2022	PRC
10. . . .	PrimeGenX Therapeutics Co., Ltd. LOGO4 (北京普祺醫藥科技股份有限公司LOGO4)	Our Company	Guo Zuo Deng Zi (國作登字)-2022-F-10010421	January 17, 2022	PRC
11. . . .	PrimeGenX Therapeutics Co., Ltd. LOGO2 (北京普祺醫藥科技股份有限公司LOGO2)	Our Company	Guo Zuo Deng Zi (國作登字)-2022-F-10010422	January 17, 2022	PRC

(d) Domain Names

As of the Latest Practicable Date, we have registered the following domain name which is material to our business:

No.	Domain name	Registrant	Registration Date	Expiry Date
1. .	primegene.net	Our Company	October 12, 2016	October 12, 2026
2. .	primegenx.net	Our Company	January 3, 2026	January 3, 2027
3. .	primegenx.bio	Our Company	January 4, 2026	January 4, 2027

Save as aforesaid, as at the Latest Practicable Date, there were no other intellectual property rights which were material to our Company’s business.

C. FURTHER INFORMATION ABOUT OUR DIRECTORS AND SUBSTANTIAL SHAREHOLDERS

1. Disclosure of Interests

(a) Interests of our Directors and the chief executive of our Company

Immediately following the completion of the [REDACTED] (assuming the [REDACTED] is not exercised), the interests and/or short positions (as applicable) of the Directors and the chief executive of our Company in the Shares, underlying Shares and debentures of the Company and any interests and/or short positions (as applicable) in shares, underlying Shares or debentures of any of

APPENDIX VI

STATUTORY AND GENERAL INFORMATION

the Company’s associated corporations (within the meaning of Part XV of the SFO) which (i) will have to be notified to our Company and the Hong Kong Stock Exchange pursuant to Divisions 7 and 8 of Part XV of the SFO (including interests and/or short positions (as applicable) which they are taken or deemed to have under such provisions of the SFO), (ii) will be required, pursuant to Section 352 of the SFO, to be entered in the register referred to therein or (iii) will be required, pursuant to the Model Code for Securities Transactions by Directors of Listed Issuers as set out in Appendix C3 to the Hong Kong Listing Rules, to be notified to the Company and the Hong Kong Stock Exchange, in each case once the [REDACTED] are [REDACTED] on the Hong Kong Stock Exchange, will be as follows:

(i) Interests in our Company

Name of Director or chief executive	Nature of interest	Number of Shares ⁽¹⁾	Approximate percentage of interest in our Company as of the Latest Practicable Date and immediately prior to the [REDACTED] ⁽²⁾	Approximate percentage of shareholding in the total [REDACTED] and outstanding share capital of our Company immediately following the completion of the [REDACTED] ⁽³⁾
Mr. Li (李雨亮) ⁽⁴⁾	Beneficial owner	56,043,356	29.16%	[REDACTED]%
	Interest in controlled corporation	27,017,544	14.06%	[REDACTED]%
Ms. Wang (王紅媚) ⁽⁵⁾	Interest of spouse	56,043,356	29.16%	[REDACTED]%
Dr. Du ⁽⁴⁾	Interest in controlled corporation	20,000,000	10.41%	[REDACTED]%
Dr. Han (韓永信)	Beneficial owner	14,288,676	7.44%	[REDACTED]%

Notes:

- All interests stated are long positions.
- The calculation is based on the total number of 192,170,424 Shares in issue as at the Latest Practicable Date.
- The calculation is based on the total number of [REDACTED] Shares in issue immediately following the completion of the [REDACTED] and without taking into account any Shares which may be [REDACTED] pursuant to the exercise of the [REDACTED].
- As of the Latest Practicable Date, Chifeng Qingxi and Chifeng Mingquan were managed by their general partner Mr. Li. Chifeng Qingxi was owned as to 40% by Dr. Du. As such, each of Mr. Li and Dr. Du is deemed under the SFO to be interested in the 20,000,000 Shares held by Chifeng Qingxi and Mr. Li is deemed under the SFO to be interested in the 7,017,544 Shares held by Chifeng Mingquan.
- Ms. Wang is the spouse of Mr. Li and is deemed to be interested in the Shares held by Mr. Li under the SFO.

(b) Interests of the Substantial Shareholders

For information on the persons who will, immediately following the completion of the [REDACTED] without taking into account any Shares which may be [REDACTED] pursuant to the exercise of the [REDACTED], have interests or short positions in our Shares or underlying Shares which would be required to be disclosed to us and the Hong Kong Stock Exchange under the provisions of Divisions 2 and 3 of Part XV of the SFO, or who will directly and/or indirectly, be interested in 10% or more of the nominal value of any class of share capital carrying the rights to vote in all circumstances at our Shareholders’ meeting, please refer to the section headed “Substantial Shareholders.”

Save as disclosed in the section headed “Substantial Shareholders,” our Directors and the chief executive of our Company are not aware of any person, not being a Director or chief executive of our Company, who has an interest or short position in our Shares, underlying Shares or debentures of our Company which, once our H Shares are [REDACTED], would have to be

APPENDIX VI

STATUTORY AND GENERAL INFORMATION

disclosed to us under the provisions of Divisions 2 and 3 of Part XV of the SFO, or who is, directly or indirectly, interested in 10% or more of the nominal value of any class of share capital carrying rights to vote in all circumstances at our Shareholders’ meeting.

2. Directors’ Service Contracts and Letters of Appointment

We [have entered] into a service contract or letter of appointment with each of our Directors. The principal particulars of these service contracts and letters of appointment include (i) the term of service, and (ii) are subject to termination in accordance with their respective term. The service contracts and letters of appointment may be renewed in accordance with our Articles of Association and the applicable Listing Rules.

Save as disclosed above, none of the Directors has entered into any service contracts or letters of appointment as a director with the Company (excluding contracts expiring or determinable by the employer within one year without payment of compensation (other than statutory compensation)).

3. Remuneration of Directors

The aggregate remuneration (including Directors’ fee, salaries, allowances and benefits in kind, discretionary bonuses, retirement scheme contributions and equity-settled share-based payments) paid to our Directors for the years ended December 31, 2024 and 2025 and the four months ended April 30, 2026 was approximately RMB14.1 million, RMB17.8 million and RMB21.5 million, respectively.

Save as disclosed above, no other payments have been made or are payable, in respect of the years ended December 31, 2024 and 2025 and the four months ended April 30, 2026 by the Company to any of our Directors.

4. [REDACTED] Share Incentive Plan

The following is a summary of the principal terms of the [REDACTED] Share Incentive Plan adopted in 2021 and amended and restated in 2026 by the Company. The terms of the [REDACTED] Share Incentive Plan are not subject to the provisions of Chapter 17 of the Listing Rules as the [REDACTED] Share Incentive Plan does not involve the grant of new options or awards by our Company to subscribe for H Shares after the [REDACTED].

Principal Terms of the [REDACTED] Share Incentive Plan

(a) Objectives

The objectives of the [REDACTED] Share Incentive Plan are to build incentive and constructive mechanisms for core employees, to achieve our medium and long-term strategies and to advance development of the Company.

(b) Eligible Participants

The participants of the [REDACTED] Share Incentive Plan include (i) employees who were department directors or above and core technical personnel as at the time of the adoption of the [REDACTED] Share Incentive Plan in 2021; (ii) other current employees who are identified by the Board as particularly outstanding; and (iii) other employees who are planned to be introduced in the future and meet the share incentive criteria of the Board.

(c) Grant of Awards

Each participant will be granted restricted shares in the form of economic interest in Chifeng Qingxi and/or Chifeng Mingquan (“**Share Incentive Platforms**”) as a limited partner (the “**Awards**”). Upon becoming the limited partner of the relevant Share Incentive Platforms, the participant indirectly receives economic interest in the number of Shares underlying the Awards granted to the participant held by the relevant Share Incentive Platforms.

APPENDIX VI

STATUTORY AND GENERAL INFORMATION

(d) Vesting Period

Upon grant of the awards and subject to completion of the formality of the equity transfer of the relevant Share Incentive Platforms, the Awards are vested.

(e) Subscription Price

The subscription price of the Awards is determined at the discretion of the Board on a case-by-case basis.

(f) Payment of the Price of the Awards

The participants shall subscribe for the Awards through self-financing methods with their own legal funds. The Company will review the legal source of the funds and will not furnish any financial support or funding to the participants. The participants shall make the corresponding payment for Awards in a full and timely manner.

(g) Administration

The [REDACTED] Share Incentive Plan shall be explained and implemented by the Board as the administrator. The Board has the authority to delegate the chairman of the Board to handle the following matters in relation to the [REDACTED] Share Incentive Plan:

- (i) determine the participants, as well as the price and quantity of the Awards;
- (ii) determine the grant date and attend to the grant procedures;
- (iii) adjust the number of Awards when certain specific events occur;
- (iv) attend to all matters related to the participants and the lock-up period;
- (v) decide on the modification and termination of the [REDACTED] Share Incentive Plan;
- (vi) manage and adjust the [REDACTED] Share Incentive Plan;
- (vii) attend to other necessary matters required for the implementation of the [REDACTED] Share Incentive Plan, save for those rights explicitly stipulated in relevant documents that need to be exercised by the shareholders' meeting of the Company; and
- (viii) attend to procedures with relevant authorities and execute relevant approval documents for the [REDACTED] Share Incentive Plan.

(h) Restrictions on Transfer

Prior to the [REDACTED], the Share Incentive Platforms may not transfer or entrust third parties to manage any or all of their interests in the Company and the participants may not dispose of the Shares underlying the Awards by any means. Within 12 months subsequent to the [REDACTED], the Share Incentive Platforms may not (i) transfer or entrust third parties to manage any or all of their interests before the [REDACTED] in the Company; or (ii) request the Company to repurchase such interests, and the participants may not dispose of the Shares underlying the Awards by any means. Beyond 12 months subsequent to the [REDACTED], the transfer or sale by the Share Incentive Platforms and the participants of their interests in the Company shall be in compliance with the pertinent applicable laws and regulations.

APPENDIX VI STATUTORY AND GENERAL INFORMATION

(i) Rights attached to the Awards

Unless otherwise specified in the respective shareholding platform partnership agreement, articles of association or the grant agreement, the eligible participants under the [REDACTED] Share Incentive Plan have the rights to any dividends or distributions from any Shares underlying the awards.

Awards Granted under the [REDACTED] Share Incentive Plan

As of the Latest Practicable Date, all limited partners of Chifeng Qingxi and Chifeng Mingquan are current employees of the Company. Save for Dr. Du and Mr. Wu, who are our Directors, the Company confirms that none of the limited partners are related parties of the Company, our Controlling Shareholders, Directors or senior management. Furthermore, there are no trust arrangements or other potential disputes regarding the equity interests held by these limited partners. Details of the Awards granted to the participants through the Share Incentive Platforms are as follows:

Chifeng Qingxi

Name of the limited partner	Position in the Company	Approximate partnership interest
Directors		
Dr. Du	Executive Director, Deputy General Manager and Chief Medical Officer	40.00%
Mr. Wu Xing (毋興)	Executive Director, Chief Financial Officer, Board Secretary and one of the joint company secretaries	16.50%
Other employees		
Mr. Zhu Li (祝力)	Senior Head of Medicinal Chemistry	15.00%
Ms. Feng Kun (馮琨)	Assistant to the Chairman	4.75%
Ms. He Baoli (和寶莉)	Head of Finance	3.50%
Ms. Zhang Hui (張慧)	Head of Biology	3.50%
Ms. Yan Chunying (閆春穎)	Associate Head of Analytical Development	3.00%
Mr. Ma Sufeng (馬蘇峰)	Head of Synthetic Chemistry	3.00%
Ms. Li Yan (李妍)	Head of Clinical Operations I	1.50%
Mr. Dai Liguang (戴麗光)	Senior Researcher	0.75%
Mr. Hu Wei (胡偉)	Senior Researcher	0.75%
Mr. Yang Yanqing (楊艷青)	Senior Researcher	0.75%
Ms. Yu Huijing (於慧靖)	Analytical Research Assistant	0.25%
Ms. Hou Fuhui (侯福會)	Senior Analytical Researcher	0.25%
Ms. Liao Jingyu (廖靖宇)	Quality Control Manager	0.25%
Ms. Zhang Zhiyan (張志艷)	Analytical Research Assistant	0.25%
Mr. Liu Liang (劉亮)	Senior Analytical Research Assistant	0.25%
Ms. Liu Yan (劉艷)	Senior Analytical Researcher	0.25%

Chifeng Mingquan

Name of the limited partner	Position in the Company	Approximate partnership interest
Employees		
Mr. Ai Lianghua (艾良華)	Chief Operating Officer/Chief Technology Officer	14.25%
Mr. Ye Dongxin (葉東鑫)	Vice President of Production Quality	14.25%

APPENDIX VI STATUTORY AND GENERAL INFORMATION

Name of the limited partner	Position in the Company	Approximate partnership interest
Employees		
Mr. Wu Mangang (吳滿剛) . . .	Head of Procurement Development	14.25%
Mr. Lei Fei (雷飛)	Senior Head of Synthetic Chemistry	5.70%
Mr. Zhang Hankang (張含康) .	Head of Quality Assurance	5.70%
Mr. Li Ming (李明)	Head of Formulation	5.70%
Ms. Li Yan (李妍)	Head of Clinical Operations I	5.70%
Ms. Wang Yanwei (王艷偉) . . .	Head of Clinical Operations II	5.70%
Mr. Wang Zaiquan (王再全) . .	Head of Formulation	5.70%
Ms. Liu Yan (劉嚴)	Head of Analytical Development	1.89%
Mr. Li Baocheng (李寶成)	Senior Formulation Researcher	1.00%
Ms. Pan Hongyan (潘紅艷) . . .	Associate Head of Regulatory Affairs	1.00%
Ms. Xiao Yanjiao (肖艷皎) . . .	Senior Regulatory Affairs Manager	0.60%
Mr. Li Yang (李揚)	Quality Assurance Manager	0.60%
Mr. Wang Zhen (王振)	Senior Synthetic Chemistry Researcher	0.60%
Ms. Sun Yang (孫陽)	Audit Manager	0.60%
Ms. Wu Chong (吳翀)	Administrative Specialist	0.20%

As of the Latest Practicable Date, there are no outstanding Awards under the [REDACTED] Share Incentive Plan and all Awards under the [REDACTED] Share Incentive Plan have been granted and vested.

5. Directors’ Competing Interests

Save as disclosed in the sections headed “Directors and Senior Management” and “Relationship with Our Controlling Shareholders” in this document, none of our Directors is interested in any business apart from our Company’s business which competes or is likely to compete, directly or indirectly, with the business of our Company.

6. Disclaimers

Save as disclosed in this document:

- (a) none of our Directors or chief executive of our Company has any interests or short positions in the shares, underlying shares and debentures of our Company or our associated corporations (within the meaning of Part XV of the SFO) which will be required to be notified to our Company and the Hong Kong Stock Exchange pursuant to Divisions 7 and 8 of Part XV of the SFO (including interests or short positions which he is taken or deemed to have taken under such provisions of the SFO) or which will be required, pursuant to Section 352 of the SFO, to be entered in the register referred to in that section, or which will be required, pursuant to the Model Code for Securities Transactions by Directors of Listed Issuers, to be notified to our Company and the Hong Kong Stock Exchange, once the Shares are [REDACTED] on the Hong Kong Stock Exchange;
- (b) so far as is known to any Director or chief executive of our Company, no person has an interest or short position in the Shares and underlying Shares which would fall to be disclosed to our Company and the Hong Kong Stock Exchange under the provisions of Divisions 2 and 3 of Part XV of the SFO, or is, directly or indirectly, interested in 10% or more of the nominal value of any class of share capital carrying rights to vote in all circumstances at our Shareholders’ meeting;

APPENDIX VI

STATUTORY AND GENERAL INFORMATION

- (c) none of our Directors, nor any of the persons listed in “— D. Other Information — 5. Qualification of Experts” below is interested in the promotion of, or in any assets which have been, within the two years immediately preceding the issue of this document, acquired or disposed of by or leased to our Company, or are proposed to be acquired or disposed of by or leased to our Company;
- (d) none of our Directors, nor any of the persons listed in “— D. Other Information — 5. Qualification of Experts” below is materially interested in any contract or arrangement with our Company subsisting at the date of this document which is unusual in its nature or conditions or which is significant in relation to the business of our Company as a whole;
- (e) save in connection with [REDACTED] Agreements, none of the persons listed in “— D. Other Information — 5. Qualification of Experts” below has any shareholding in our Company or the right (whether legally enforceable or not) to subscribe for or to nominate persons to subscribe for securities in our Company;
- (f) none of our Directors has entered or has proposed to enter into any service agreements with our Company (other than contracts expiring or determinable by the employer within one year without payment of compensation other than statutory compensation); and
- (g) save as contemplated under the [REDACTED] Agreements, none of our Directors, their respective associates (as defined under the Hong Kong Listing Rules), or Shareholders who are interested in more than 5% of the issued share capital of our Company has any interest in our Company’s five largest customers and five largest suppliers.

D. OTHER INFORMATION

1. Estate duty

Our Directors have been advised that no material liability for estate duty is likely to fall on our Company.

2. Litigation

As of the Latest Practicable Date, our Company was not engaged in any litigation, arbitration or claim of material importance, and no litigation, arbitration or claim of material importance was known to our Directors to be pending or threatened by or against our Company, that would have a material adverse effect on its business, financial condition or results of operations.

3. Joint Sponsors

The Joint Sponsors satisfy the independence criteria applicable to sponsors set out in Rule 3A.07 of the Hong Kong Listing Rules.

The Joint Sponsors will receive an aggregate fee of approximately US\$[REDACTED] million for acting as the sponsors for the [REDACTED].

4. No Material Adverse Change

Our Directors confirm that, up to the date of this document, there has been no material adverse change in the financial or trading position or prospects of our Company since April 30, 2026 (being the date to which the latest audited financial statements of our Company were prepared).

APPENDIX VI STATUTORY AND GENERAL INFORMATION

5. Qualification of Experts

The following are the qualifications of the experts (as defined under the Hong Kong Listing Rules and the Companies (Winding Up and Miscellaneous Provisions) Ordinance) who have given opinions or advice which are contained in this document:

Name	Qualification
CITIC Securities (Hong Kong) Limited	Licensed corporation under the SFO to conduct type 4 (advising on securities) and type 6 (advising on corporate finance) as defined under the SFO
CMBC International Capital Limited	Licensed to conduct Type 1 (dealing in securities) and Type 6 (advising on corporate finance) of regulated activities under the SFO
KPMG	Certified Public Accountants Public Interest Entity Auditor registered in accordance with the Accounting and Financial Reporting Council Ordinance
Fangda Partners	Legal advisors as to PRC Law
Beijing HuanRun Law Firm	Legal advisor as to PRC intellectual property laws
Frost & Sullivan (Beijing) Inc., Shanghai Branch Co.	Industry consultant

6. Consents of Experts

Each of the experts as referred to in “— D. Other Information — 5. Qualification of Experts” has given and has not withdrawn their respective written consents to the issue of this document with the inclusion of their reports and/or letters and/or legal opinion (as the case may be) and references to their names included in the form and context in which it respectively appears.

None of the experts named above has any shareholding interests in our Company or the right (whether legally enforceable or not) to subscribe for or to nominate persons to subscribe for securities in our Company.

7. Promoters

The promoters of our Company are as follows:

No.	Name of promoters of our Company
1. . . .	Li Yuliang (李雨亮)
2. . . .	Han Yongxin (韓永信)
3. . . .	Huang Shuo (黃碩)
4. . . .	Ai Lianghua (艾良華)
5. . . .	Chifeng Qingxi (赤峰清溪)
6. . . .	Chifeng Mingquan (赤峰名泉)
7. . . .	Beijing Kaiyuan Hongdao Venture Capital Center (Limited Partnership) (北京開元弘道創業投資中心(有限合夥))
8. . . .	Chongqing Xianfeng Qiyun Equity Investment Partnership (Limited Partnership) (重慶險峰旗雲股權投資合夥企業(有限合夥))

APPENDIX VI STATUTORY AND GENERAL INFORMATION

No.	Name of promoters of our Company
9. . . .	Hangzhou Yuhang Lapam Healthcare Equity Investment Fund Partnership (Limited Partnership) (杭州余杭龍磐健康醫療股權投資基金合夥企業(有限合夥))
10. . .	Xizang Zhifan Enterprise Management Consulting Center (Limited Partnership) (西藏智梵企業管理諮詢中心(有限合夥))
11. . .	Nanjing Lestar Medical Technology Partnership (Limited Partnership) (南京力思達醫療科技合夥企業(有限合夥))
12. . .	Chifeng Zaiji Enterprise Management Center (Limited Partnership) (赤峰再極企業管理中心(有限合夥))

Save as disclosed in this document, within the two years immediately preceding the date of this document, no cash, securities or other benefit has been paid, [REDACTED] or given nor are any proposed to be paid, [REDACTED] or given to any promoters in connection with the [REDACTED] and the related transactions described in this document.

8. Preliminary Expenses

We have not incurred any material preliminary expense.

9. Taxation of Holders of H Shares

The sale, purchase and transfer of H Shares are subject to Hong Kong stamp duty if such sale, purchase and transfer are affected on the [REDACTED] of members of our Company, including in circumstances where [REDACTED] are affected on the Stock Exchange. The current rate of Hong Kong stamp duty for such sale, purchase and transfer is 0.2% of the consideration or, if higher, the fair value of the H Shares being sold or transferred (the buyer and seller each paying half of such stamp duty). In addition, a fixed duty of HK\$5.0 is currently payable on any instrument of transfer of H Shares.

10. Application for [REDACTED]

The Joint [REDACTED] has made an application on behalf of our Company to the [REDACTED] Committee for the [REDACTED] of, and permission to deal in, the H Shares. All necessary arrangements have been made to enable the securities to be admitted into [REDACTED].

11. Binding Effect

This document shall have the effect, if an application is made in pursuance of this document, of rendering all persons concerned bound by all of the provisions (other than the penal provisions) of Sections 44A and 44B of the Companies (Winding Up and Miscellaneous Provisions) Ordinance insofar as applicable.

12. Bilingual Document

The English language and Chinese language versions of this document are being published separately, in reliance upon the exemption provided by Section 4 of the Companies (Exemption of Companies and Prospectuses from Compliance with Provisions) Notice (Chapter 32L of the Laws of Hong Kong).

This document is written in the English language and contains a Chinese translation for information purpose only. Should there be any discrepancy between the English language of this document and the Chinese translation, the English language version of this document shall prevail.

APPENDIX VI

STATUTORY AND GENERAL INFORMATION

13. Miscellaneous

Save as disclosed in this document,

- (a) within the two years immediately preceding the date of this document, neither we nor any of our subsidiaries has issued or agreed to issue any share or loan capital fully or partly paid up either for cash or for a consideration other than cash;
- (b) no share or loan capital of our Company or any of our subsidiaries is under option or is agreed conditionally or unconditionally to be put under option;
- (c) within the two years immediately preceding the date of this document, no commissions, discounts, brokerage or other special terms have been granted in connection with the issue or sale of any shares or loan capital of our Company;
- (d) within the two years immediately preceding the date of this document, no commission has been paid or payable (except commission to [REDACTED]) to any persons for subscription, agreeing to subscribe, procuring subscription or agreeing to procure subscription of any shares of our Company or any of our subsidiaries;
- (e) no founder, management or deferred shares of our Company or any of our subsidiaries have been issued or agreed to be issued;
- (f) there is no arrangement under which future dividends are waived or agreed to be waived;
- (g) since April 30, 2026 (being the date on which the latest audited financial statements of our Company were made up), there has been no material adverse change in our financial or trading position or prospects;
- (h) there has not been any interruption in the business of our Company which may have or have had a material adverse effect on the financial position of our Company in the 12 months immediately preceding the date of this document;
- (i) our Company has no outstanding convertible debt securities or debentures; and
- (j) Our Company currently does not intend to apply for the status of a foreign investment joint stock limited company.